Mr. Gabriel Fahel reports

CYBIN TO RELEASE PHASE 2 TOPLINE SAFETY AND EFFICACY DATA FOR CYB003 IN MAJOR DEPRESSIVE DISORDER AND HOST R&D BRIEFING ON NOVEMBER 30, 2023

Cybin Inc. will host a research and development briefing on Thursday, Nov. 30, 2023, in New York at 10 a.m. ET.

Institutional investors, analysts and company guests are cordially asked to save the date for this important coming session, which will feature an overview of the company's recently completed phase 1/2 trial of CYB003, and a detailed review of the top-line safety and efficacy data.

Featured speakers will include members of Cybin's leadership and scientific teams along with key neuroscience opinion leaders.

A live webcast of the event will be available on the company's investor relations website on the events and presentations page.

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

We seek Safe Harbor.